Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Treatment updates in Merkel cell carcinoma

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 862
Rating:

Dr Paul Nghiem - University of Washington, Seattle, USA

Dr Nghiem speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the latest finding in the field of Merkel cell carcinoma. He highlights that there have been major developments in the settings of first-line treatment, treatment after chemotherapy and the neoadjuvant setting.

He goes on to discuss the importance and benefit of immune therapy over chemotherapy in this setting.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation